Table 1.
Baseline patient characteristics.
| Variables | UR-LA (n = 108) | UR-M (n = 360) | p-Value |
|---|---|---|---|
| Age (years), median (range) | 69(38–84) | 67(33–86) | 0.15 |
| Male/female, n (%) | 54(50)/54(50) | 210(58.3)/150(41.7) | 0.12 |
| ECOG PS, n (%): 0/1/2 | 86(79.6)/18(16.6)/4(3.8) | 218(60.5)/127(35.2)/15(4.2) | 0.0004 |
| Tumor location, n (%) | |||
| Head/Body-tail | 73(67.6)/35(32.4) | 148(41.1)/212(58.9) | <0.0001 |
| Tumor size (mm) | 38(20-76) | 40(15-83) | 0.062 |
| CA19-9 (U/L) | 237(1.1-8949) | 580(1-12219) | <0.0001 |
| Extent of disease, n (%) | |||
| Localized | |||
| Metastatic site | 108(100) | ||
| Liver | 193(53.6) | ||
| Peritoneum | 123(34.2) | ||
| Lung/LN/Other | 15(4.2)/23(6.4)/6(1.6) | ||
| Treatment, n (%) | |||
| GEM | 17(15.7) | 125(34.7) | |
| GEM + Erlotinib | 2(1.9) | 14(3.9) | |
| S-1 | 5(4.6) | 38(10.6) | |
| GS | 31(28.7) | 42(11.6) | |
| GnP | 13(12.0) | 63(17.5) | |
| FOLFIRINOX | 12(11.1) | 21(5.8) | |
| S-1or GnP or GS plus PTX (i.p. + i.v.) | 0(0) | 43(11.9) | |
| Chemoradiotherapy | 27(25) | 10(2.8) | |
| Other | 1(0.9) | 4(1.1) |
UR-LA: unresectable locally advanced pancreatic cancer, UR-M: metastatic pancreatic cancer, PS: performance status, GEM: gemcitabine, GS: S-1 combined with gemcitabine, GnP: nab-paclitaxel combined with gemcitabine, PTX: paclitaxel.